Clarus (CLAR) Launches 2.75M Share Offering

Clarus Corporation (NASDAQ: CLAR), announced that it intends to offer, subject to market and other conditions, 2,750,000 shares of common stock registered under the Securities Act of 1933, as amended. The Company also expects to grant to the underwriters an option for 30 days to purchase up to an additional 412,500 shares of common stock.

The Company intends to use the net proceeds from the offering for general corporate purposes, including repayment of debt, capital expenditures and potential acquisitions.

BofA Securities is acting as lead book-running manager and representative of the underwriters for the offering. Stifel, Raymond James and Roth Capital Partners are also acting as book-running managers.

This common stock offering is being made pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-254105) filed with the Securities and Exchange Commission (“SEC”). The offering is being made solely by means of a prospectus supplement and accompanying prospectus which has been filed with the SEC. Before you invest, you should read the prospectus supplement and accompanying prospectus, as well as other documents the Company has filed or will file with the SEC for more complete information about the Company and the offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the Company, any underwriter or any dealer participating in the offering will arrange to send the prospectus supplement relating to the offering to you if you request it by contacting BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001 or by e-mailing [email protected].

This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security and does not constitute an offer, solicitation or sale of any security in any jurisdiction in which such offer, solicitation or sale would be unlawful.

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• Bio-key International (BKYI) Receives Notice of Non-Compliance from Nasdaq
• INmune Bio (INMB) Prices 572K Share Offering at $8.32/sh